• Productivity is increased as a range different analyses can be performed on the same system, replacing multiple conventional analytical techniques
 • Multi-attribute methods can be deployed that reduce the number of analyses required to monitor biotherapeutic quality​
 • It is a sensitive technique that allows detection of low level analytes and impurities​
 • It provides information-rich data that helps guide decision-making

Fully automated system set-up and an intelligent health system that continuously monitors system performance ensure that: ​

 • The system is always producing data of the required quality​
 • Data quality is consistent from user to user and system to system​
 • Any issues are rapidly diagnosed and resolved​

This gives confidence that decisions are always being made based on good data and ensures productivity by maximising system uptime and minimising reanalysis.

The system has tailored workflows for:​

 • CONFIRM Sequence
 • Intact mass analysis (proteins, nucleic acids, synthetic peptides)​
 • Peptide mapping​
 • Peptide MAM (multi-attribute method)​
 • Released N-glycan analysis​

These workflows streamline method set-up, analysis, data processing and report generation to deliver the required information rapidly.​

For more information about our dedicated workflows on waters_connect, please visit the waters_connect for biopharmaceuticals webpage.

​The system is also suited for a range of other applications required in biotherapeutic process and product development including:​

 • Cell culture media analysis​
 • Lipid nanoparticles​
 • mRNA capping

To find out how Waters can support your Bioprocess Development needs please visit our dedicated webpage.

Efficient separation is achieved using ultraperformance liquid chromatography (UPLC) enhanced by unique MaxPeak High Performance Surfaces (HPS) developed for the ACQUITY Premier UPLC system and columns. These deliver​:

 • High sensitivity for challenging acidic peptides​
 • High sensitivity for acidic glycans​
 • Higher sensitivity and higher productivity for oligonucleotide analysis by removing the need for passivation​

MS data are generated using the ACQUITY RDa high resolution mass detector which was designed to deliver the required performance for biotherapeutic monitoring.​

In head-to-head test in customer laboratories the ACQUITY RDa has been shown to give equivalent results to larger, higher cost and more complex advanced characterization systems for the relative quantification of peptide attributes.

The BioAccord LC-MS System with ACQUITY Premier is a complete system that has called on Waters’ core competencies of: ​

 • Chromatography systems​
 • Mass spectrometry​
 • Chemistry​
 • Informatics and compliance​
 • Service and application training / support​

​
It is delivered as a complete system.  Installation is performed with application-specific specification tests. This is followed by training by our professional services team with methods and training material for biopharmaceutical analysis.​

​The BioAccord LC-MS System with ACQUITY Premier is easily deployed in non MS expert environments, with no need to reinvent routine labs organization and headcount.​

To maintain data integrity the system operates on the compliant-ready waters_connect informatics platform which allows BioAccord Systems to be networked.​

​Information and data continuity across the organization can be ensured as BioAccord shares a common informatics platform with our Q-Tof LC-MS/MS systems. Advanced characterization and routine analysis systems can be connected on the same network allowing seamless access of methods and data.